

Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective November 13, 2014, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than Generic Program:

- **Baraclude, Carac, Exforge, Patanase and Pepcid suspension will be added** to the Program.
- **Solaraze, and Tobradex will be removed** from the Program.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- **Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.**
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION

Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense as Written/Product Selection Code of '1'; **Pharmacies can submit any valid NCPDP field (408-D8) value.**

List of Brand Name Drugs included in this program* (Updated 10/30/14):

Accolate	Diovan HCT	Patanase
Adderall XR	Epivir HBV	Pepcid suspension
Alphagan P 0.15%	Exforge	Pulmicort Respules
Aldara	Felbatol	Soriatane
Astepro	Focalin XR(15mg,30mg,45mg)	Symbyax
Bactroban cream	Gabitril 2mg & 4mg	Tegretol suspension
Baraclude	Hepsera	TOBI
Carac	Kadian	Toprol XL
Carbatrol	Lidoderm	Trileptal suspension
Catapres-TTS	Mepron	Trizivir
Combivir	Myfortic	Wellbutrin
Depakote sprinkle	Niaspan	Wellbutrin XL
Diastat	Ortho Evra	

*List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.